CORT
"Three of Corcept's Cushing's durability defenses cracked inside 90 days, yet the balance sheet has $532M cash, zero debt, and a newly FDA-approved oncology asset. At ~4x FY26 guide, is the market pricing a fragile revenue stream or a fragile company?"
Corcept Therapeutics is a specialty pharmaceutical company whose FY2025 $761M revenue base is concentrated almost entirely in the Korlym Cushing's syndrome franchise (branded plus authorized generic). Between December 2025 and February 2026, three principal durability defenses degraded materially: the Federal Circuit ruled against Corcept in Teva v. Corcept (patent), the FDA issued a Complete Response Letter on relacorilant for Cushing's (lifecycle extension), and the Q4 specialty pharmacy transition left $65-90M in scripts undispensed (channel). Against that, Lifyorli was approved four months ahead of PDUFA on 2026-03-25 for platinum-resistant ovarian cancer, the balance sheet carries $532M cash with zero debt, and the pipeline spans four SGRA molecules across five-plus indications.
Executive Summary
Cross-lens roll-up assessment
Corcept is mid-transition. The current $761M revenue base is fragile and the fragility is recent rather than structural - three principal Korlym durability defenses degraded inside a 90-day window in late 2025 and early 2026. At the same time, a fortress balance sheet ($532M cash, zero debt, $142M FCF), a four-months-early Lifyorli FDA approval with 7-year orphan exclusivity, and a four-molecule SGRA pipeline provide runway and optionality. The market is pricing multiple adverse scenarios simultaneously at roughly 4x FY26 guide, which the committee reads as over-bearish given the fact pattern - but only if Lifyorli executes and the relacorilant Cushing's CRL resolves via resubmission rather than a new trial.
The committee converged on a middle-band readout across every signal: FRAGILE + CONTESTED/DEFENSIBLE boundary + GAP_BEARISH + QUESTIONABLE + MIXED governance + ELEVATED tail risk. None of these are alarming in isolation, but their simultaneity, the recency of the fragility (90-day window), and the binary April 2026 FDA meeting all warrant deeper investigation before any allocation decision. The balance sheet removes going-concern risk, so AVOID is not the right label. But the number of middle-band readings that could tip either direction on Q1 2026 data, the April FDA meeting, Lifyorli Q2/Q3 launch metrics, and the first Form 4 executions under the new 10b5-1 plans argue for HIGHER_SCRUTINY rather than PROCEED_WITH_CAUTION. The UNDERPRICED reading is real but the MEDIUM confidence on it against HIGH confidence on FRAGILE means the asymmetry works only if the 20-25% bear weight holds against the market's implied ~45%.
Key Takeaways
- •REVENUE_DURABILITY is FRAGILE: Three of four principal defenses for the Cushing's franchise weakened in 90 days - Teva Federal Circuit loss on patent (Feb 2026), relacorilant Cushing's CRL on lifecycle extension (Dec 2025), and a specialty pharmacy channel miss that left $65-90M in Q4 2025 scripts undispensed. Authorized generic at 78% of tablet volume adds ongoing per-patient price compression. Lifyorli is a real offset but contributes 'only a small portion' of 2026 per the CFO.
- •FUNDING_FRAGILITY is RESILIENT: $532M cash, zero debt, $142M FY25 FCF, no covenants, no maturities. Under the stress scenario (Korlym -25% + Medicaid compression + sticky SG&A + slow Lifyorli ramp), runway is 4-5 years. Compound-failure scenario compresses runway to roughly 24 months at 10-18% probability. The balance sheet cannot break in any conventional sense.
- •COMPETITIVE_POSITION is DEFENSIBLE (boundary case): Aggregate moat rests on Lifyorli 7-year orphan exclusivity and SGRA platform validation via the four-months-early approval. Per-indication, the revenue-generating Korlym franchise is CONTESTED. Trajectory likely passes through CONTESTED in 2028 as Korlym compression outpaces Lifyorli ramp, then potentially recovers on pipeline milestones (MONARCH, DAZALS).
- •NARRATIVE_REALITY_GAP is GAP_BEARISH while EXPECTATIONS_PRICED is UNDERPRICED: EV/sales of 3.6-4.0x on $900M-$1B FY26 guide implies terminal Cushing's decline, near-zero Lifyorli credit (~$200M vs $500M-$2B comparable), and near-zero pipeline option value. The analyst-constructed market-implied bear weight is ~45% against a fact-pattern-supported 20-25%. Separately, the management narrative runs GAP_BULLISH on the $3-5B relacorilant forecast and 'diversified oncology company' framing.
- •GOVERNANCE_ALIGNMENT is MIXED (two independent lenses): Revenue-only compensation design and 10b5-1 plan-adoption timing by the CFO and endocrinology franchise president 18-22 days pre-CRL create durable optics concerns. Director Baker's $3.3M open-market purchase during active personal litigation, director-level retained stakes of 6.3M shares, zero debt, and no related-party transactions push in the opposite direction. Structural asymmetry - directors retain, officers monetize - is the signal rather than any single transaction.
- •ACCOUNTING_INTEGRITY is QUESTIONABLE (not CONCERNING): A $33.2M tax benefit reduced the visible earnings decline from -59% pre-tax to -29% net. The $245M reported buyback figure includes $72.9M of tax-withholding on equity comp; diluted weighted-average shares still grew 5.7%. A new $2.56M long-term Medicaid rebate accrual appeared at 12/31/2025 coincident with AG reaching 78% volume share. Presentation asymmetries are material but OCF/NI conversion is 1.42, the auditor is EY with an unqualified opinion implied, and no channel stuffing or non-GAAP gamesmanship is present.
- •TAIL_RISK_SEVERITY is ELEVATED: Compound failure scenarios at 7-11% joint probability produce 40-70% equity compression and thesis invalidation. The SGRA mechanism-class safety scenario (4-11% over 18 months) is the single-mechanism concentration risk no ordinary lens owns. A hostile or opportunistic acquisition at a compressed valuation ($27-32) emerged as an adversarially-identified scenario neither analyst originally constructed, with 30-45% conditional probability on a dual-execution or regulatory-plus-governance stress.
Key Tensions
- •FRAGILE current revenue coexists with UNDERPRICED equity. The two are not contradictory - FRAGILE describes the current revenue stream's dependency structure; UNDERPRICED describes market-implied scenario weights against the full fact pattern (balance sheet floor, Lifyorli approval, pipeline breadth). A reader with tighter bear priors would reasonably arrive at FRAGILE + FAIRLY PRICED instead.
- •The aggregate moat is DEFENSIBLE while the franchise generating 100% of 2025 revenue is CONTESTED at the indication level. Aggregate DEFENSIBLE rests on forward-looking Lifyorli orphan exclusivity and platform validation, not backward-looking Korlym franchise defense. If Lifyorli under-delivers in Year 1 (sub-$50M run rate), both the moat and the UNDERPRICED thesis re-rate downward simultaneously.
- •Management narrative runs GAP_BULLISH while market narrative runs GAP_BEARISH. Both are true on different timeframes. Management's $3-5B relacorilant forecast and 'diversified oncology company' framing run ahead of near-term reality; the market's ~$200M Lifyorli credit runs behind the fact pattern. The operative Myth Meter signal is the market gap; management over-statement becomes a qualitative credibility discount on forward forecasts.
- •Capital deployment retrospective is MIXED while point-in-time funding is RESILIENT. The balance sheet absorbs the cost of past deployment quality issues (buyback disclosure gross-up, SG&A front-running the CRL, buybacks at ~$44 while the stock now trades $33-40) without retroactively vindicating them. Both labels coexist stably.
- •The April 2026 FDA meeting on relacorilant Cushing's is binary across multiple signals. Resubmission path improves REVENUE_DURABILITY trajectory, holds DEFENSIBLE, and reduces ELEVATED regulatory exposure. A new-trial requirement strands $80-150M of SG&A buildout, deepens FRAGILE, and pressures DEFENSIBLE toward CONTESTED.
Gravy Gauge
Is this revenue durable?
Key Metrics
Key FindingsClick to expand details
Signal AssessmentsClick for full context
| Signal | Scale | Assessment | Evidence |
|---|---|---|---|
Revenue Durability | — | FRAGILE | 2Corroborated |
Regulatory Exposure | — | ELEVATED | 2Corroborated |
Model Debates
Cross-Lens Insights
Where Lenses Agree
- ✓Buyback disclosure gross-up confirmed by Fugazi Filter and Stress Scanner: $245M headline combines $172.9M open-market with $72.9M tax-withholding on equity comp; diluted WA shares still +5.7%; open-market at ~$44 avg vs stock now $33-40
- ✓Teva Federal Circuit February 2026 loss flagged by Gravy Gauge and Moat Mapper as primary Korlym franchise moat and durability hit; 50-80% of branded revenue at risk on third-party ANDA entry over 12-36 months
- ✓Director Baker 100K-share open-market buy at $33.14 on 2026-03-17 flagged by Myth Meter, Insider Investigator, and Stress Scanner as substantive alignment signal with partial litigation-optics discount; all three note market is not crediting this
- ✓Revenue-only 2026 DEF 14A Company Selected Measure identified by Fugazi Filter and Stress Scanner as structural driver of observed 1,440bps operating margin compression over two years - mechanism fingerprinted independently by both lenses
- ✓Maduck (12/8/2025) and Mokari (12/12/2025) 10b5-1 plan adoption 18-22 days before Cushing's CRL (12/30/2025) flagged by Fugazi Filter and Insider Investigator; cooling-off compliance satisfied but MNPI-at-adoption unresolved from public record
- ✓New $2.56M long-term accrued government rebate line at 12/31/2025 (vs $0 prior year) coincident with Korlym AG reaching 78% volume share flagged by Fugazi Filter, Stress Scanner, and Gravy Gauge as first visible Medicaid best-price compression signal
- ✓$532M cash + zero debt + $142M FCF balance sheet confirmed by Gravy Gauge, Stress Scanner, and Moat Mapper as reason FRAGILE/CONTESTED/MIXED middle-band readings do not translate into going-concern risk - provides 4-5 year runway under stress
Where Lenses Differ
REVENUE_DURABILITY vs EXPECTATIONS_PRICED
Different objects. FRAGILE describes current revenue stream dependency structure; UNDERPRICED describes market-implied scenario weights given full fact pattern (balance sheet, Lifyorli, pipeline). Myth Meter's explicit read is that bear scenarios are over-weighted at ~45% vs analyst 20-25%.
FUNDING_FRAGILITY vs CAPITAL_DEPLOYMENT
Temporal decomposition. RESILIENT is point-in-time balance sheet; MIXED is three-year retrospective on deployment quality. The balance sheet absorbs past deployment mistakes (buyback gross-up, SG&A front-running CRL, buybacks at $44 avg vs current $33-40, revenue-only CSM) without retroactively vindicating them.
COMPETITIVE_POSITION (aggregate vs per-indication)
Lens flags explicitly as boundary case with LOW confidence. Aggregate DEFENSIBLE rests on forward-looking Lifyorli orphan exclusivity plus SGRA platform validation; trajectory predicted to pass through CONTESTED in 2028 trough year before potential pipeline-driven recovery.
NARRATIVE_REALITY_GAP (management vs market)
Both gaps are real on different timeframes and audiences. Management narrative ($3-5B relacorilant forecast maintained post-CRL, 'diversified oncology company' framing, 'never been more confident' across three guide cuts) runs ahead of near-term reality. Market narrative (Lifyorli priced as exit opportunity, near-zero pipeline option value) runs behind fact pattern.
GOVERNANCE_ALIGNMENT (insider vs institutional)
Both lenses converge on MIXED from different evidence. Insider Investigator identifies two-tier ownership (directors retain, officers monetize) as the structural signal. Fugazi Filter identifies revenue-only compensation design as the mechanism driving margin compression, offset by clean institutional posture.
The following publicly available documents were collected and extracted into a structured fact dossier that powered this analysis.
SEC Filing
- Annual Report (10-K) — FY2025
- Quarterly Report (10-Q) — Q3 2025
- Quarterly Report (10-Q) — Q2 2025
- Proxy Statement (DEF 14A) — 2026
- Current Report (8-K) — Lifyorli FDA Approval (2026-03-25)
- Current Report (8-K) — Q4 2025 Earnings (2026-02-24)
- Current Reports (8-K) — 20 filings (May 2024 - March 2026)
- Form 4 Insider Transactions — 20 filings (Feb-Apr 2026)
- Form 144 Proposed Sales — 10 filings (Nov 2025-Apr 2026)
Earnings Transcript
- Q4 2025 Earnings Call Transcript
- Q3 2025 Earnings Call Transcript
- Q2 2025 Earnings Call Transcript
- Q1 2025 Earnings Call Transcript
Research Document
- CourtListener Litigation Search — 10 cases (incl. Ritchie derivative C.A. 2022-0102-BWD)
Web Source
- Greenhouse Job Postings — 43 listings (commercial buildout signals)